科伦博泰生物-B:TROP2ADC具备BIC潜力 全球多中心三期临床积极拓展

天风证券
Aug 06, 2025

携手默沙东深耕TROP2 ADC 全球布局,具有BIC 潜力芦康沙妥珠单抗(SKB264)是公司自主研发的一款靶向TROP2 的ADC 药物,海外权益已授权给默沙东。该药物目前已进入十多项实体瘤适应症的三期全球多中心注册临床研究阶段。根据默沙东规划,SKB264 将在2027 年迎来9 项临床试验数据的集中披露,并被列为具有“重磅炸弹”潜力的候选产品,显示出默沙东对其商业价值与差异化定位的高度认可...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10